FDA Clears Gleamer’s ChestView AI Software for CXR
Adjunctive use of the AI-powered software led to an average 38.6 percent increase in the detection of pneumothorax by general radiologists, according to a 2023 study.
The Food and Drug Administration (FDA) has granted 510(k) clearance for ChestView, an artificial intelligence (AI)-enabled software, which may enhance detection of a variety of abnormalities on chest X-rays (CXRs).
In a 2023 retrospective study involving 500 patients, researchers found that adjunctive use of the ChestView software led to an average increased detection of 26.2 percent for pneumothorax, 8.5 percent for pleural effusion and 14.1 percent for consolidation.
Without AI assistance, only two out of 12 reviewing radiologists were able to detect a right paravertebral mass in the case above. With the use of the newly FDA cleared AI software ChestView, all 12 radiologists detected the mass. (Images courtesy of Radiology.)
The authors of the study, published in Radiology, also noted an overall mean 31 percent reduction in CXR reading time with the use of ChestView. Specifically, researchers pointed out a 27 percent reduction in CXR reading time for thoracic radiologists and a 30 percent reduction for radiology residents.
"We believe ChestView will transform how chest X-rays are analyzed, making healthcare delivery faster, safer, and more effective for millions of patients,” noted Christian Allouche, the chief executive officer at Gleamer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Study Suggests AI Software May Offer Standalone Value for X-Ray Detection of Pediatric Fractures
April 9th 2025Artificial intelligence (AI) software demonstrated a 92 percent sensitivity for detecting fractures in a study involving over 1,600 X-rays from a tertiary pediatric emergency department.
AMA Approves Category III CPT Codes for AI-Enabled Perivascular Fat Analysis from CT Scans
April 9th 2025Going into effect in 2026, the new CPT codes may facilitate increased adoption of the CaRi-Heart software for detecting coronary inflammation from computed tomography scans pending FDA clearance of the technology.
